ReviewAdvances in experimental medicine and biology2025
Development of Standardized Methods and Analytical Tools.
Review in Advances in experimental medicine and biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Deciphering reprogramming efficiency in human induced pluripotent stem cells: insights from the generation of 150 cell lines.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reprogramming of somatic cells to generate induced pluripotent stem cells (iPSCs) has significantly advanced regenerative medicine and drug discovery. This chapter explores the diverse methods and conditions for generating iPSCs from various adult cell sources, highlighting their potential in autologous and allogeneic therapies. Key considerations for iPSC generation include the choice of reprogramming factors and systems, somatic cell sources, culture media conditions, and methods for identifying and characterizing iPSCs. High-quality materials, defined processes, and robust analytical methods are essential to ensure the safety, efficiency, and reproducibility of iPSCs. This chapter also discusses the importance of regulatory compliance, including the use of xeno-free materials and adherence to regulatory guidelines. Additionally, advances in semi-automated and automated processing are anticipated to enhance process control and reduce variability. The combination of qualified reagents, defined xeno-free workflows, and comprehensive characterization assays significantly enhances the transition of iPSC technology from research to clinical applications, paving the way for more reliable and scalable regenerative therapies and advancing the field of personalized medicine.
Indexed as
Identifiers
41136850What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.